 Brent, you have one of the most fascinating critical mineral companies in my personal opinion in that you have the full supply chain from mining and exploration to the actual product and you already have distribution in place. Would you say that's accurate? Yes, absolutely. So I'm not even sure where to start. Other than I was reading your objectives, your plan is to expand international markets in the latter half of 2024 and you're working through FDA requirements towards launching sales in the US and Europe in the second quarter of 2025. Those were some of the highlights I picked up on. Are those correct? Yes, the FDA, it's all dependent on our next financing but we anticipate by the end of 2025 will be in the US market and the European market will follow after that. But it's right now we're focused on launching our products in Canada, in the next six months we'll have all our products tested and ready for market and we're also signing distribution deals with international companies that accept Health Canada licensing and they are looking at selling our products throughout the globe really so we have multiple distributors that we're in talks with. We've signed our first distribution agreement recently and we have more pending. We have PO's that we're working on and the Canadian market is ready for our products and we have multiple clinics and the Alberta government is also a big supporter of our project moving forward. So for those of you out there going Voyager, Pharmaceuticals, what is this company? Our company, Voyager, boasts five licensed barium contrast products targeting significant shortages in second and third world countries but you're looking at commencing manufacturing of your barium contrast products by as early as May this year, is that correct? That's right. We have a contract manufacturer who is moving forward and funding our product lines so they are we're getting all our inventory in ready to start manufacturing and using third party manufacturing and bringing in foreign barium sulfate to make our barium contrast for the radiology drug market. So we have our Health Canada approvals, we're rolling out in Canada and we're rolling out internationally. Well, speaking of that, I read that you're estimating $2 million in revenue after the first year and a potential to capture up to 30% of a market generating up to $160 million and this is an incredibly lucrative market. This is a very small segment. Can you help everybody out there that might be new to barium contrast products with what we're talking about here? Well, there's about a $600 million a year market for barium contrast used in CT and X-ray. It's a oral contrast that is used to help doctors delineate between your tissues and potential issues like tumors and it's widely used and we have the purest barium sulfate discovery out in Francis Creek in BC. We are moving forward to build a quarry and mine our own ingredients which will reduce our cost tenfold than what we're currently paying for for barium sulfate and this will put us in a very competitive position moving forward. Okay. I also read that following your initial sales in Canada, you're going to immediately and I've watched you for a couple of years so these types of aggressive milestones do not surpass me from you. You plan to start your construction of API processing plant incorporating innovative technologies like the Raincage Carbon Neutral Eden system. Okay. What does any of that mean? Explain it to us please. So we're very fortunate to be partnered with Raincage Carbon Inc. who are of a new technology that extracts CO2 from exhaust streams plus all the other pollutants and they have this technology where the carbon that comes off of that machine is a carbon fullerene. So it's a complex molecule that has anywhere from, it's like a soccer ball like the picture behind me is a carbon 60 fullerene ball and you can get carbon 60, carbon 70, carbon 120 and we're working with Raincage where we can put a molecule inside there where they just announced that they successfully and commercially have created the first vanadium fullerene called the metafullerene where they have a vanadium molecule inside and we're going to start working with that to create a new MRI drug and that would be very disruptive because each one of those atoms has electrons and those electrons actually enhance the atom that's inside making it a super molecule so to speak which in radiology will allow us to create new drugs that are better than what's out there in the marketplace. My understanding of this 18 month bill aims to boost gross margins upwards of 26 to 70%. I personally love your marketing deck and you have your new product, you have an introduction of SmoothX, love the name okay, Elon Musk has got to love that. Can you tell us more about your SmoothX launch? SmoothX, we began moving forward with SmoothX, we found that the market requested that we come out with our full suite of products so we've gone head on and started developing those products, we have them formulated, we're currently undergoing bench testing with those products and moving forward into patient testing here. So within a six month timeframe we expect to have the full suite of products that we're rolling out into Canada in the international markets and we believe that we're going to take a very good piece of that market as we move forward over the next year. Of course I can't let you go without drawing everyone's attention to your commitment to ESG, your environmental commitment and sustainability goals. Would you like to talk and share the vision for Voyager Pharmaceuticals with our audience please Brent. Voyager is going to be the first carbon-neutral pharmaceutical company utilizing this Eden system from carbon, Rancage Carbon, which allows us to produce a revenue stream from carbon capture. So their systems are unique in that it generates revenue, it's not a burden, it's a moneymaker and that revenue is going to finance our company moving forward to build out on our iodine contrast in the US and to build out our large pharmaceutical facility in Alberta to become a major player in this business. Brent, thank you so much for the update today and for everybody out there going, okay I need to know more about Voyager Pharmaceuticals, please go to their website, great marketing deck, you can access it all there, thank you so much Brent. Thank you very much.